Natus Medical: The Losing Streak Continues
Natus Medical (NASDAQ:BABY) traded at a new 52-week low today of $7.54. This new low was reached on below average trading volume as 84,000 shares traded hands, while the average 30-day volume is approximately 205,000 shares.
Over the past year, Natus Medical has traded in a range of $7.54 to $17.50 and are now at $7.56. The 200-day and 50-day moving averages have moved 0.81% lower and 0.94% lower over the past week, respectively.
Natus Medical Incorporated is a medical device company that develops, manufactures, and markets screening products. The Company’s products identify and monitor common medical disorders that may occur between conception to a baby’s first birthday. Natus is selling its ALGO products for newborn hearing screening, as well as its CO-Stat products for the evaluation of jaundice.
Natus Medical (NASDAQ:BABY) has potential upside of 58.7% based on a current price of $7.56 and analysts’ consensus price target of $12.00. Natus Medical shares should first meet resistance at the 50-day moving average (MA) of $8.80 and find additional resistance at the 200-day MA of $13.19.
- Sleep Deprivation Among Firefighters
- Consumers with Obstructive Sleep Apnea not being Offered the Appropriate Care
- Department of Transporatation Wants Sleep-Apnea Data Made Available
- Birth of an Industry Leader
- The Third Pillar of Health
- Validation of Transcend Auto™ Autotitrating CPAP Compared with an Established AutoPAP Device
- HST: Is anyone HOME?